PRODUCTS from the Genetic Engineering and Biotechnology Center (CIGB) contribute to the diagnosis, prevention and treatment of close to 30 disorders, announced Dr. Verena Muzio, director of clinical research at this institution.
The disorders include chronic hepatitis, respiratory papillomatosis, codylomata, conjunctivitis and other viral illnesses, she specified, during an event celebrating the 26th anniversary of the CIGB, founded July 1, 1986 by the leader of the Cuban Revolution, Fidel Castro.
One outstanding medicament manufactured by the Center is Heberprot-P, used to treat diabetic ulcers in feet, which has benefited 70,000 patients in many countries, avoiding amputation in the majority of cases.
Muzio highlighted the impact of the Heberbiovac national immunization program against acute hepatitis B. This drug was the first vaccine produced by CIGB to be certified by the World Health Organization.
In this context, she noted that 12 million doses of the vaccine have been administered in Cuba since 1992, and the total population protected against the disease is in excess of four million.
There has been no case of acute hepatitis B in minors under five years of age since 1999, the director stated.
With more than 20 years’ experience, Heberbiovac is available in 40 countries and more than 150 million doses have been administered, Muzio emphasized.
Currently, some 12 products are at different stages of clinical trials prior to obtaining certification. These include cancer treatments and therapeutic vaccines against infectious diseases. (AIN) •